Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

9.11.22

News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

5.10.21

Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

20.12.23

Press Release

Topadur Pharma AG and Juvic Inc. Kick-starts Transnational Collaboration project

Topadur Pharma AG and Juvic Inc. Launch Transnational Collaboration for the Disease Management of Systemic Sclerosis

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Scientific Publication in Pharmaceutics

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

Topadur Pharma AG and Juvic Inc. Kick-starts Transnational Collaboration project

About us

Approach

Disease Areas

Investors

Contact